Stay updated on AT2220 Safety Study in Pompe Disease Clinical Trial
Sign up to get notified when there's something new on the AT2220 Safety Study in Pompe Disease Clinical Trial page.

Latest updates to the AT2220 Safety Study in Pompe Disease Clinical Trial page
- Check3 days agoChange DetectedThe page metadata has been updated to version v3.0.2 with new date stamps (2025-09-11, 2025-09-09, 2025-09) and an 'Estimated' last update label, replacing older v3.0.1 metadata from 2018. No substantive changes to core content (pricing, stock, or time slots) were detected.SummaryDifference1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.3%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, while removing specific details about previous location terms and certain medical classifications related to glycogen storage disease.SummaryDifference3%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has added information about a clinical study evaluating the safety and tolerability of duvoglustat in Pompe disease, including details about the study's design, eligibility criteria, and outcomes. Additionally, the page now includes a disclaimer stating that the U.S. government does not review or approve all studies listed.SummaryDifference100%
Stay in the know with updates to AT2220 Safety Study in Pompe Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AT2220 Safety Study in Pompe Disease Clinical Trial page.